Clinical trialsCompany release

Traws Pharma: ratutrelvir matches Paxlovid on symptom resolution in final Phase 2a COVID-19 data

🇺🇸 Traws Pharma, Inc. (TRAW) · Thu 12 Nov 2026

Final results from the 92-patient study show comparable recovery times and no viral rebound to Day 28, while the company readies a tivoxavir marboxil resubmission for Q4 2026.

Traws Pharma announced on 12 November 2026 the final results of its Phase 2a study of ratutrelvir, an oral, ritonavir-free antiviral, in patients with mild-to-moderate COVID-19. The study enrolled 92 patients and compared ratutrelvir with Paxlovid.

Median symptom resolution was comparable between the two treatments, at 13.5 days for ratutrelvir and 14.5 days for Paxlovid. The company reported no viral rebound through Day 28.

On safety, treatment-related adverse events occurred in 1 of 32 patients given ratutrelvir, against 4 of 30 patients given Paxlovid. The summary available does not break down the remaining participants or describe the nature of these events.

Traws also said it has completed a tablet bridging study and a toxicology retest for tivoxavir marboxil, its candidate for influenza prophylaxis. The company plans a regulatory resubmission in the fourth quarter of 2026.

For ratutrelvir, Traws intends to discuss with the US Food and Drug Administration a possible registration path for patients who are ineligible for Paxlovid. No timeline for that discussion was given in the information provided.

What it means for your team

  • Phase 2a data are early-stage and small; the arms of 32 and 30 patients limit what can be concluded on comparative efficacy or safety.
  • The ritonavir-free design is relevant to the Paxlovid-ineligible population, which the company is positioning as its regulatory focus with the FDA.
  • Regulatory teams should watch for the tivoxavir marboxil resubmission in Q4 2026, which follows the tablet bridging and toxicology work.
  • Details of the FDA discussions on a registration path have not been disclosed, so no assumptions on acceptable endpoints or populations can yet be made.

Company's press release (SEC filing): Traws Pharma, Inc. ↗

Article written by VigiEye from the official source (Traws Pharma, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →